Results 121 to 130 of about 31,381 (233)

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K, Pritam Kumar Roy, Maniklal Shee, Budhaditya Mukherjee, Aoife Ward Gahlawat, Mahitosh Mandal   +5 more
wiley   +1 more source

Nitric Oxide in Cancer: Mechanisms, Dual Role, and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Nitric oxide exerts concentration‐dependent dual roles in cancer, functioning as either a tumor promoter or suppressor. This review comprehensively examines NO's multifaceted regulation of tumor biology, including S‐nitrosylation signaling, metabolic reprogramming, immunemodulation, and therapy resistance, and highlights emerging therapeutic strategies
Jia Shao, Honghua Zhang, Jingyu Chen, Ziyu Qian, Ning Zhang, Yihua Zhang, Hui Ye, Jianbing Wu, Zhangjian Huang   +8 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

Proline‐Derived N‐Heterocyclic Carbene Gold(I) Complexes With Dual DNA Binding and Thioredoxin Reductase Inhibition

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Proline‐derived Au(I)–NHC complexes display potent anticancer activity against lung and triple‐negative breast cancer cells. The cationic complexes promote DNA intercalation, thioredoxin reductase inhibition, ROS overproduction, and mitochondrial membrane depolarization, ultimately triggering apoptotic cell death through a multimodal mechanism of ...
Giacomo Cassarà, María Gil‐Moles, Thomas Scattolin, M. Concepción Gimeno   +3 more
wiley   +1 more source

Exploring the Anticancer Activity of Ruthenium(II)–Arene and Copper(I) Complexes Bearing N‐Heterocyclic Carbene Ligands Containing Azido, Pyridinium, and Ethisterone‐Derived Triazole Groups

European Journal of Inorganic Chemistry, Volume 29, Issue 24, 21 August 2026.
A versatile library of backbone‐functionalized N‐heterocyclic carbene (NHC) ligands was developed and efficiently converted into Cu(I) and Ru(II) NHC complexes, demonstrating that ligand functionalization strongly modulates anticancer activity, with Cu(I)–NHC species showing potent and selective antiproliferative effects against ovarian and breast ...
Alessia Schiavo, Chiara Tupini, Nicola Demitri, Ilaria Lampronti, Thomas Scattolin   +4 more
wiley   +1 more source

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

International Journal of Cancer, Volume 159, Issue 4, Page 936-950, 15 August 2026.
What's new? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar, Marco Strecker, Thomas Wartmann, Wenjie Shi, Frederike Stelter, Maximilian Doelling, Mihailo Andric, Or Kakhlon, Christian Täger, Denny Schanze, Michael Linnebacher, Michael Naumann, Daniel E. Stange, Dörthe Jechorek, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, Volume 32, Issue 30, 13 August 2026.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, Volume 20, Issue 8, Page 2114-2128, August 2026.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source